About
Noetik is an AI-native biotech using advanced machine learning and proprietary data to discover and develop precision cancer therapies. The founding team includes key leaders from Recursion and the Parker Institute for Cancer Immunotherapy (PICI), namely Ron Alfa MD, PhD (CEO), Jacob Rinaldi, PhD (CSO), Lacey Padron, PhD, (CTO), with a track record of building technology enabled platforms and advancing drugs from discovery to clinical development. The team has built one of the most significant proprietary multimodal lung cancer datasets for machine learning, and demonstrated target discovery using self supervised learning models. Noetik's models, built on human translational clinical data, enable biomarker selection and patient stratification, as well as target discovery, to identify the right drugs for the right patients.
Ron Alfa, M.D. Ph.D., CEO, CO-FOUNDER
Ron Alfa is a physician scientist at the forefront of leveraging technology to tackle unmet therapeutic needs in medicine. He is Co-Founder and CEO of Noetik, a next generation precision oncology company using multimodal foundation models pre-trained on large-scale human tumor data to discover cancer therapeutics. Prior to founding Noetik, Ron was Senior Vice President, Head of Research and acting-CSO at Recursion, where he led the company’s scientific organizations and portfolio strategy. At Recursion, he led portfolio and platform builds across rare disease, Neuroscience, Oncology, and Immunology, and was responsible for advancing multiple therapeutic programs from discovery to clinical development. Ron holds an M.D. and Ph.D from Stanford University School of Medicine, where he completed his doctoral work in Neuroscience, and has a M.A. in History of Medicine from UCL (University College London).
Jacob Rinaldi, Ph.D., CSO, CO-FOUNDER
Prior to founding Noetik, Jacob Rinaldi was the Head of Oncology at Recursion. Jacob has extensive computational biology experience from Genentech in deep learning for cancer vaccines, target discovery for breast cancer, transfer learning for IO biomarkers, high-dimensional data visualization, next-gen SERDs. Jacob holds a Ph.D from Stanford University in Neuroscience.